---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-006501"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-08-17T10:04:44+00:00"
generated_at: "2026-08-17T10:10:20.128824+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Valion Bio terminates CEO, appoints COO, secures $1.5M funding from 3i

## Summary
- CEO Michael K. Handley terminated effective Aug 16, 2026; Lisa Wolf appointed COO, remains CFO.
- Letter Agreement with 3i, LP: $1.5M for 1,500 Series B Preferred at $1,000/share plus warrants.
- Second closing of $1.5M for another 1,500 shares if definitive side letter executed by Aug 24, 2026.
- Royalty Agreement: 5% of Velocity Bioworks gross revenue for 10 years to 3i and other purchasers.
- Stockholders approved reverse stock split (1:5 to 1:50) at special meeting.

## SEC filing metadata
- accession: 0001683168-26-006501
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-08-17T10:04:44+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/0001683168-26-006501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826006501/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-006501
- JSON: https://secwatch.observer/filing/0001683168-26-006501.json
- Plain text: https://secwatch.observer/filing/0001683168-26-006501.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.